Lupin's Indore facility fails to clear regulatory test again
Drugmaker Lupin on Saturday said it has again received six observations from the US health regulator after the inspection of its Indore facility in Madhya Pradesh. The company's Indore and Goa facilities had received a warning in 2017 over quality control issues. The Mumbai-based drugmaker recently recalled drugs from the US market due to the presence of particulate matter.